On August 21, 2023, B. Braun (Thailand) Ltd., a world-renowned medical technology company based in Germany, inked a Memorandum of Agreement (MoA) with the Ramathibodi Comprehensive Cancer Centre (RCCC), Faculty of Medicine Ramathibodi Hospital, Mahidol University.
Their collaborative endeavour is aimed at developing educational programs for an ambulatory home-based chemotherapy model, which can be applied and practiced in healthcare settings to enhance the capabilities of healthcare professionals. Managing Director Mr. Sayan Roy represented B. Braun (Thailand) Ltd., while Assoc. Prof. Ekaphop Sirachainan, M.D., Chairman of RCCC, and Phichai Chansriwong, M.D., Oncologist, Faculty of Medicine Ramathibodi Hospital, signed on behalf of RCCC. Assoc. Prof. Surasak Leela-Udomlipi, M.D., Director of Ramathibodi Hospital, delivered a warm welcome speech.
The development of professional competence in ambulatory home-based chemotherapy is a pivotal step in improving caregiving and the outcomes for cancer patients. This collaboration aims to elevate the standard guidelines for developing home-based chemotherapy models within workplaces for healthcare personnel in the Asia Pacific region. It will enhance their skills and capabilities through various training programs.
The signing of this MoA underscores B. Braun's dedication to "Sharing Expertise" through its Aesculap Academy, a leading medical education arm committed to strengthening the skills of healthcare professionals, with the ultimate goal of protecting and enhancing the health of people worldwide.
Assoc. Prof. Ekaphop Sirachainan, MD., Chairman of Ramathibodi Comprehensive Cancer Centre, expressed his enthusiasm, stating, "On behalf of the Ramathibodi Comprehensive Cancer Centre, Faculty of Medicine Ramathibodi Hospital, we are delighted to collaborate with B. Braun Thailand and Aesculap Academy to develop an education program focused on ambulatory home-based chemotherapy services for healthcare personnel and nurses from various hospitals in the Asia Pacific. RCCC has been established since 2014, and we have maintained a longstanding relationship with B. Braun Thailand. This educational collaboration will expand knowledge about home-based chemotherapy treatment, address delays in chemotherapy schedules due to insufficient hospital beds, and result in cost savings. Patients undergoing
home chemotherapy will achieve outcomes on par with traditional treatment methods, saving costs and improving their quality of life. We anticipate that this education program will benefit all participants and serve as a guiding light for international practice in the future."
Mr. Sayan Roy, Managing Director, B. Braun (Thailand) Ltd.
Mr. Sayan Roy, Managing Director of B. Braun (Thailand) Ltd., remarked, "We are honoured to partner with the esteemed Ramathibodi Comprehensive Cancer Centre as we work together to advance cancer treatment and improve the health of patients worldwide. This collaborative effort reflects our shared belief in the transformative power of exchanging knowledge and sharing expertise. Through this partnership, we are committed to creating meaningful opportunities for healthcare professionals and patients alike. As a leading medical device company, our collaboration with experts will drive effective improvements in education and, consequently, cancer treatments across the region. Our ultimate goal is to advance cancer treatment and enhance the quality of life for patients."
The signing ceremony was attended by representatives from the Ramathibodi Comprehensive Cancer Centre and the management team from B. Braun (Thailand) Ltd., reaffirming their commitment to the vision of "protecting and improving the health of people around the world."
